To improve the therapeutic effect of cancers and HIV in new way

For a long time, retinoblastoma protein (pRB) has been studied in cell growth and cancer prevention. Now, in a new study, the scientists discovered a new role for pRB through research using recombinant human proteins, which not only enhances cancer efficacy, but also works to treat other diseases, such as HIV.

Most of the DNA that is recombined in the human genome is called "junk DNA", and these are relics of the past that usually do not play any role and are quietly present. If they start to copy, they will re-enter the human gene, bringing diseases such as cancer.

The team found that binding of pRB to another protein called EZH2 keeps these "junk DNA" in silence, whereas pRB acts as a vector. EZH2 is transported to a repeating sequence.

This new discovery breaks the cancer genetic experts' understanding of pRB and EZH2, and most researchers have never thought that these two widely-existing proteins in the DNA have such an effect. "This opens up a myriad of gates for the treatment of multiple diseases, including antitoxic drugs, which allow patients to have multiple choices during treatment," the researchers said.

The new study also shows that EZH2 inhibitors help the immune system find cancer cells. They can block EZH2 and wake up the "junk DNA", so the cancer cells will appear in the immune system, as if infected by the same virus. The immune system will target cancer cells and kill them.

The findings also help other diseases, such as HIV, are also "junk DNA" hidden in the immune cells. Because the immune system can't detect these "junk DNA", so the patients are always HIV positive. EZH2 inhibitors can make these "junk DNA" become lively and show themselves so that we can use the existing drugs on the market for treatment.

"Over the years, we have been working on pRB, but we have never thought about it, and it is now clear that the combination of pRB-EZH2 is effective in treating a variety of diseases," the researchers said. By the way, Flarebio provides you with good-quality recombinant proteins including recombinant CDH15 at great prices.

Scientists have discovered the key factor NLRC3 which inhibits colon cancer

Immunologists at the St. Jude Children's Research Institute in the United States recently discovered a key class of NLRC3 that inhibits colon cancer through recombinant human proteins. The research led by Thirumala-Devi Kanneganti, Ph.D., of the Department of Immunology was published in the recently published Nature journal.

In the initial experiments, the researchers found that the removal of protective NLRC3 protein increased the development of colon cancer and also confirmed the NLRC3 tumor suppressor pathway key molecules so as to protect the treatment of colon cancer mechanism and provides a new drug target. NLRC3 belongs to a class of NLR "receptor" molecules with the regulation of the immune system and other cytological functions. However, up to now, the development of NLRC3 inhibiting tumor is still unclear.

The researchers found that NLRC3 mainly play a role in colonic epithelial cells and can be directly against infection or tumor cell development caused by intestinal inflammatory response. "All of these experimental designs are complementary and can further help us to confirm the function of NLRC3, which is essential for protecting the body from the proliferation of abnormal cells." When the NLRC3 gene is missing, the tumor will develop "Suggests Kanneganti". This suggests that if we can find a way to clinically induce high expression of NLRC3, we can block the signaling pathways leading to tumorigenesis," Kanneganti said.

"The most important thing to improve the activity of the NLRC3 molecule is to precisely determine the signaling pathways and mechanisms involved in the regulation of this molecule in the cell," says Kanneganti. The researchers revealed that NLRC3 plays a "brake" role in the PI3K-mTOR pathway, which usually starts early in the development of the tumor. "The development of direct drug therapy for the PI3K-mTOR pathway is very difficult because the pathway is central to cell signaling," says Kanneganti. "Therefore, we can target the NLRC3 molecule itself to block early development of tumor cells."

Despite the preliminary clarity of the mechanism of action, the team believes that the role of NLRC3 not only to prevent the occurrence and development of tumors in some infectious and inflammatory diseases, there should still be a lot we don't know about the role. From a broader perspective, further in-depth study could elucidate the function of other NLR family members. "NLR family functions are diverse. They not only can regulate the immune system and inflammatory response, but also can block the tumor production process," Professor Kanneganti said, "No one would link NLR family protein and PI3K-mTOR pathway together previously, so this study makes people particularly excited, because it is likely to open a new door to studying the functions of NLR." Flarebio provides superior recombinant proteins including recombinant ECE1 at great prices.

Researchers discover new method of hijacking cells for viruses

DNA contains instructions on how cells make the desired substance. According to research using recombinant dog proteins, when cells need proteins, the relevant parts of the DNA will be transcribed, and transcripts called messenger RNA will leave the nucleus and enter the manufacturing machinery as templates to produce new proteins.

In this process, RNA can be edited in a variety of ways. It may be added to the additional instructions and may also be enemy control. Viruses can edit RNA information to create the version of the protein it needs to produce thousands of copies of the virus. Over the past few decades, biologists have a clearer understanding of how viruses hijack host cells.

Many viruses control the day-to-day running of cells by sending out messages that interfere with the ability to turn off unwanted cellular functions and enhance the functionality they require. But biologists at the University of California, San Diego, have recently discovered that there are some more hijacking mechanisms for viruses that are more subtle and more complex. They don't block cell information but change the content of the information.

The study is published in Nature Structural and Molecular Biology. By the way, Flarebio is a National High-Tech Enterprise with research, production and sales as one. Flarebio provides you with good-quality recombinant proteins like recombinant CDH15 for your research.

Scientists reveal the role of ARID1A in the regulation of active agent enhancers

Scientists have developed a set of model systems in mice through a lot of recombinant rat proteins, and it allows them to carefully observe how mutant proteins in human cancers play a role in tumor silencing. Not all cancers are caused by direct changes in the genetic code. Epigenetic events can also lead to abnormal gene expression induced by cancer. The study published in the Natural Genetics explains how the epigenetic process carries out gene regulation and induce colon cancer.

"The ARID1A mutation is widespread in human cancers and the development of experimental model systems is important to help us understand how gene mutations induce disease," said Dr. Charles W. M. Roberts, director of the St. Jude Children's Research Comprehensive Cancer Center.

ARID1A is an integral part of the SWI / SNF chromatin remodeling complex. Chromatin remodeling has a profound effect on gene expression. Chromatin remodeling of protein-coding genes in human cancers is the most common variant of the gene.

The researchers said, ARID1A can inhibit the tumor in the mouse colon, but it can't play a inhibition role in the small intestin. They found that penetration enhancers and shorter DNA regions are important components of the interaction of ARID1A with the SWI / SNF chromatin remodeling complex.

Scientists have revealed the role of ARID1A in the regulation of active agent enhancers, resulting in loss of control of the cellular identity ARID1A in the colon and inducing the formation of cancer.

The new model system will play a role in future work. "The systems we develop are important for understanding why dye modification mutations are so frequent in cancer, revealing the mechanisms that lead to colon tumor growth and studying potential therapeutic interventions." By the way, Flarebio offers good-quality recombinant proteins like recombinant CDH15 at good prices.

Experimental drugs can effectively prevent rejection of mice heart transplants

According to a new study by scientists at Weill Cornell Medicine and Brigham and Women's Hospital through recombinant human proteins, experimental drugs that block the activation of immune cell components effectively prevent rejection of mice heart transplants.

The findings published in the Proceedings of the National Academy of Sciences on December 12 describe a compound developed by medical researchers at Weill Cornell. The inhibits the cellular structure known as the immune proteasome while avoiding constitutive proteasomes. Proteasomes help cells to break down regulatory proteins to regulate their behavior. The constitutive proteasome is present in all cells, while the immunoproteasome is expressed predominantly in the cells of the immune system.

The currently-approved proteasome inhibitors also target two types of proteasomes. They are used in transplantation medicine to block immune cell function and reduce graft rejection. However, proteasome inhibitors in all cells of the body can cause toxicity in transplanted organs and hosts. The researchers demonstrated that their compound DPLG3, a highly selective and reversible inhibitor of the immune proteasome, only shuts down the immune proteasome, leaving the constitutive proteasome. DPLG3 reduces the number of immune cells in the graft. Inhibitors also increase the expression of "exhaustive markers" on the remaining immune cells. Exhaustive markers are typical of immune cells, reducing the ability to attack foreign cells. These changes protect the organ from rejection, while protecting the body from toxic side effects of non-selective proteasome inhibitors, such as bone marrow and nervous system damage.

"Transplant patients often have to take long-term toxic, broad-spectrum immunosuppressive agents, which increases the risk of infection, cancer and toxicity of the graft itself," said Dr. Carl Nathan, director of Department of Microbiology and Immunology and RA Rees Pritchet, professor of microbiology, and Cornell's professor of medical microbiology and immunology and medicine, "Selective blocking of the immune proteasome without affecting the constitutive proteasomes in other host cells and transplant organ cells can help patients to receive grafts on a long-term basis and improve organ transplants."

Medical researchers of Weill Cornell led by Dr. Gang Lin, associate professor of microbiology and immunology, co-author of the study, designed DPLG3, which is highly selective for the immune proteasome and is highly selective for long-term exposure. Dr. Nathan and Dr. Lin are co-inventors of the DPLG3 and have submitted patents. Flarebio offers good quality recombinant proteins such as recombinant PIGR at competitive prices.

New drug has been developed to treat lung cancer

According to a new study presented at the European Society for Clinical Oncology in Copenhagen, through research using recombinant horse proteins, researchers have developed a novel antibody that boosts the immune system against tumor cells. In patients with non-small cell lung cancer (NSCLC), it is more effective than conventional chemotherapy.

In Phase III clinical trials, patients who were not previously treated took the drug called pemumab and showed more frequent efficacy and longer lifespan. After 10 months, they developed a disease progression compared to receiving chemotherapy of the patients less. More specifically, compared with chemotherapy alone, the drug reduced the likelihood of cancer progression by half and reduced overall mortality by 40%.

The effect of this new drug is so good that scientists can't believe that they simply suspend the clinical trials so that all patients are replaced by this drug. Their clinical findings have been published in the New England Journal of Medicine. "Be mindful of this day. This is a new era of lung cancer treatment," researcher Stefan Zimmermann said in an interview in Lausanne, Switzerland.

Pemumab, developed by Merck, has been approved by the FDA as a second-line treatment for patients with advanced head and neck cancer, but its first-line treatment has not been confirmed. In an early clinical trial, a similar drug called naduzumab did not achieve the desired results, and the results showed that it was not more effective in the treatment of lung cancer than chemotherapy.

But the new clinical trial is specifically for NSCLC patients. Most cancer cells in these patients contain a protein called PD-L1 that prevents white blood cells from unnecessarily killing healthy cells, but also helps the cancer cells to be destroyed. According to the research team, about a quarter of NSCLC patients with advanced disease are consistent with this description.

Compared to traditional methods of care, pumu monoclonal antibody reduced the mortality of these patients by 40% in the experiment. In another small clinical trial, the researchers found that if combined paimuomab with chemotherapy, the effect is even more significant. Flarebio offers high-quality recombinant proteins like recombinant TLR2 at good prices.

Newly-developed drug for Alzheimer's disease is expected to come out

US researchers conducted a series research using recombinant mouse proteins and published a paper in the November 2, 2016, saying that they confirmed that the new drug Verubecestat in the clinical trial phase of Alzheimer's disease (AD) does not bring harmful side effects, and the effect of the drug as agentia is worthy waiting.

The study published in the US medical journal Science Translational Medicine refers, "From the beginning of the experiment that they began investigating 32 patients with varying degrees of Alzheimer's disease, now there are more than 3,000 patients participate in the experiment. The team also launched two comprehensive large-scale clinical trials."

In the treatment, the experts selected the compound Verubecestat developed by the US pharmaceutical company. Verubecestat is able to inhibit the BACEI enzyme and reduce the amount of β-amyloid.

One of the pathological features of Alzheimer's disease (AD) is the presence of amyloid plaques (β-amyloid deposits) in the brain. Such plaques not only severely affect memory, but also have significant influence on protein generation. Although BACEI enzyme inhibitors in the past have a certain effect, it often brings liver dysfunction, neuropathy and other serious side effects.

In this clinical trial, the specialists plan to verify the effectiveness of Verubecestat through three treatment stages. Now they have entered the third test phase and plan to draw the final test conclusions in July, 2017. If the results are good, then Verubecestat will enter market in 2-3 years as new treatment drug. By the way, Flarebio provides you with superior recombinant proteins like recombinant TLR2 at competitive prices.